Clinical trials: Irritable Bowel Syndrome
Irritable Colon
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.
- Trial name
- NCT00385099
- Testing
- GW876008
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome with Diarrhea
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
- Trial name
- NCT04492787
- Testing
- Changkang Granule
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Constipation-predominant Irritable Bowel Syndrome (IBS-C)
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
This study is to investigate the efficacy, safety, and plasma concentration change of ASP0456 in patients with constipation-predominant irritable bowel syndrome.
- Trial name
- NCT01714843
- Testing
- linaclotide
- Where
- 4 sites in Japan
- Volunteers
- 559 people
- Sponsor
- Astellas Pharma Inc
IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease)
Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade…
- Conditions
- IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease), Gut Health
- Trial name
- NCT07699926
- Testing
- Postbiotic supplementation
- Where
- Malaysia
- Volunteers
- 55 people
- Sponsor
- My Myracle Sdn.Bhd
Irritable Bowel Syndrome
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GSK3179106 is a potent and relatively selective inhibitor of RET kinase which has been designed to be a safe and effective therapy for irritable bowel syndrome (IBS) patients .
- Trial name
- NCT02727283
- Testing
- GSK3179106
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diarrhea Predominant Irritable Bowel Syndrome
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
- Trial name
- NCT01896583
- Testing
- ASP7147
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seldar Pharma, Inc.
Patients With Irritable Bowel Syndrome With Diarrhea
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase II clinical trial. Its purpose is to evaluate the efficacy and safety of Huanghou Zhixie Diwan in subjects with irritable bowel…
- Trial name
- NCT07721012
- Testing
- Huanghou Zhixie Diwan group, Huanghou Zhixie Diwan mimic
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Lei Yunshang Group
Irritable Bowel Syndrome
Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS
Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome.
- Trial name
- NCT05348642
- Testing
- pasteurized A. muciniphila
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00215566
- Testing
- DDP733
- Where
- 15 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Dynogen Pharmaceuticals